Abstract:The main problem of Helicobacter pylori (H. pylori) infection management is linked to antibiotic resistances. This phenomenon has grown in the last decade, inducing a dramatic decline in conventional regimen effectiveness. The causes of resistance are point mutations in bacterial DNA, which interfere with antibiotic mechanism of action, especially clarithromycin and levofloxacin. Therefore, international guidelines have recently discouraged their use in areas with a relevant resistance percentage, suggesting first-line schedules with expected high eradication rates, i.e., bismuth containing or non-bismuth quadruple therapies. These regimens require the daily assumption of a large number of tablets. Consequently, a complete adherence is expected only in subjects who may be motivated by the presence of major disorders. However, an incomplete adherence to antibiotic therapies may lead to resistance onset, since sub-inhibitory concentrations could stimulate the selection of resistant mutants. Of note, a recent meta-analysis suggests that susceptibility tests may be more useful for the choice of first than second-line or rescue treatment. Additionally, susceptibility guided therapy has been demonstrated to be highly effective and superior to empiric treatments by both meta-analyses and recent clinical studies. Conventional susceptibility test is represented by culture and antibiogram. However, the method is not available everywhere mainly for methodology-related factors and fails to detect hetero-resistances. Polymerase chain reaction (PCR)-based, culture-free techniques on gastric biopsy samples are accurate in finding even minimal traces of genotypic resistant strains and hetero-resistant status by the identification of specific point mutations. The need for an invasive endoscopic procedure has been the most important limit to their spread. A further step has, moreover, been the detection of point mutations in bacterial DNA fecal samples. Few studies on clarithromycin susceptibility have shown an overall high sensitivity and specificity when compared with culture or PCR on gastric biopsies. On these bases, two commercial tests are now available although they have shown some controversial findings. A novel PCR method showed a full concordance between tissue and stool results in a preliminary experience. In conclusion, despite poor validation, there is increasing evidence of a potential availability of noninvasive investigations able to detect H. pylori resistances to antibiotics. These kinds of analysis are currently at a very early phase of development and caution should be paid about their clinical application. Only further studies aimed to evaluate their sensitivity and specificity will afford novel data for solid considerations. Nevertheless, noninvasive molecular tests may improve patient compliance, time/cost of infection management and therapeutic outcome. Moreover, the potential risk of a future increase of resistance to quadruple regimens as a consequence of their use on large scale and incomplete patient adherence could be avoided.

Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing

Review article: the global emergence of Helicobacter pylori antibiotic resistance

Helicobacter pylori Antimicrobial Resistance and the Role of Next-Generation Sequencing

Updates to the Diagnosis and Clinical Management of Helicobacter pylori Infections

Advances in Diagnostic Modalities for Helicobacter pylori Infection

Testing for Helicobacter pylori in an era of antimicrobial resistance

Diagnosis of Helicobacter pylori: Changes towards the Future

Change in Diagnosis of Helicobacter pylori Infection in the Treatment-Failure Era

Diagnosis of Helicobacter pylori Infection and Recent Advances

Noninvasive molecular analysis of Helicobacter pylori: Is it time for tailored first-line therapy?

Advances on diagnosis of Helicobacter pylori infections

Evaluation of Multiplex ARMS-PCR for Detection Ofhelicobacter Pylorimutations Conferring Resistance to Clarithromycin and Levofloxacin

Genotype profiles of from gastric biopsies and strains with antimicrobial-induced resistance

Oligonucleotide Microarray: A New Rapid Method for Screening the 23S Rrna Gene of Helicobacter Pylori for Single Nucleotide Polymorphisms Associated with Clarithromycin Resistance

Current Helicobacter pylori Diagnostics

Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies for Helicobacter pylori Infections

Helicobacter Pylori Diagnosis and Therapy in the Era of Antimicrobial Stewardship.

From Antibiotic Resistance to Antibiotic Renaissance: A New Era in Helicobacter pylori Treatment

Evolution of Diagnostic Methods for Helicobacter pylori Infections: From Traditional Tests to High Technology, Advanced Sensitivity and Discrimination Tools

Genotype profiles of Helicobacter pylori from gastric biopsies and strains with antimicrobial-induced resistance.

Treatment of Helicobacter pylori infection: Past, present and future